HCIA
FATE icon

Hochman Cole Investment Advisors’s Fate Therapeutics FATE Stock Holding History

Hochman Cole Investment Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,471
Closed -$141K – 109
2018
Q2 		$141K Sell
12,471
-5,093
-29% -$56.1K 0.09% 105
2018
Q1 		$171K Sell
17,564
-16,633
-49% -$159K 0.12% 98
2017
Q4 		$209K Sell
34,197
-5,641
-14% -$25.2K 0.13% 95
2017
Q3 		$158K Buy
+39,838
New +$135K 0.1% 97
2017
Q1 		– Sell
-10,887
Closed -$27K – 89
2016
Q4 		$27K Buy
+10,887
New +$29.1K 0.02% 89
2016
Q3 		– Sell
-11,005
Closed -$19K – 85
2016
Q2 		$19K Sell
11,005
-5,336
-33% -$9.67K 0.02% 76
2016
Q1 		$29K Hold
16,341
– – 0.02% 78
2015
Q4 		$55K Buy
+16,341
New +$68.7K 0.05% 76

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Hochman Cole Investment Advisors's FATE Position: Q3 2018 in Review

Hochman Cole Investment Advisors sold out of Fate Therapeutics (FATE) in Q3 2018, closing a stake of 12,471 shares — an estimated $141K sold.

Hochman Cole Investment Advisors first reported a position in FATE in Q4 2015 and held it in 8 quarters. The position peaked at $209K in Q4 2017. 116 funds tracked by Wall St. Rank hold FATE as of Q3 2018.

  • Hochman Cole Investment Advisors reported no remaining Fate Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Hochman Cole Investment Advisors sold 12,471 Fate Therapeutics shares in Q3 2018, an estimated $141K.
  • Hochman Cole Investment Advisors first reported a position in Fate Therapeutics in Q4 2015 and held it in 8 quarters.
  • Hochman Cole Investment Advisors's Fate Therapeutics position peaked at $209K in Q4 2017.
  • 116 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2018.

Based on Hochman Cole Investment Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.